InvestorsHub Logo
Followers 122
Posts 6384
Boards Moderated 0
Alias Born 08/17/2014

Re: TomP1 post# 15428

Tuesday, 04/19/2016 12:51:27 PM

Tuesday, April 19, 2016 12:51:27 PM

Post# of 34604
No this is one of the two studies without a checkpoint inhibitor that they are funding, under c. From their PR:

TapImmune has announced its plans to initiate, in 2016, several clinical trials with TPIV 200 vaccine including: a) a 280 patient Phase II trial in triple-negative breast cancer funded by a grant from the U.S Department of Defense (DOD) to the Mayo Clinic; b) a combination trial with a checkpoint inhibitor in ovarian cancer; and, c) at least two additional trials funded and administered by TapImmune
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News